enVVeno Medical Corporation Warrants
NVNOW
NVNOW was delisted on the 26th of May, 2023.
1 hedge funds and large institutions have $2K invested in enVVeno Medical Corporation Warrants in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
78% less capital invested
Capital invested by funds: $9K → $2K (-$7K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $2K | -$4.13K | -6,802 | -64% |
|
NVNOW Hedge Fund Activity: Q3 2018 in Review
1 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical Corporation Warrants (NVNOW) for Q3 2018, worth a combined $2K — down 78% from $9K a quarter earlier.
Fund positioning in NVNOW was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $4.13K.
- 1 institutional investor held enVVeno Medical Corporation Warrants (NVNOW) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $2K of enVVeno Medical Corporation Warrants stock for Q3 2018, down 78% quarter-over-quarter.
- 0 funds opened new enVVeno Medical Corporation Warrants positions in Q3 2018 and 0 closed out.
- The largest enVVeno Medical Corporation Warrants seller in Q3 2018 was UBS Group, an estimated $4.13K sold.
Based on aggregated 13F filings for Q3 2018.